PMID- 12738973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 37
IP  - 11
DP  - 2001 Nov
TI  - Esomeprazole: A significant advance beyond omeprazole in the treatment of 
      acid-related disease.
PG  - 767-781
AB  - The second-generation proton pump inhibitor (PPI) esomeprazole is a new chemical 
      entity consisting of an optical isomer of omeprazole, which for many years has 
      been acknowledged as the gold standard therapy in gastric acid-related disorders. 
      Esomeprazole has demonstrated a unique pharmacokinetic profile and enhanced 
      efficacy over omeprazole, with improved inter-patient pharmacokinetic consistency 
      and a similar safety profile. Esomeprazole has been tested as a therapeutic agent 
      in the management of erosive esophagitis, symptomatic gastroesophageal reflux 
      disease (GERD) and, in combination with appropriate antibiotic therapy, for the 
      eradication of the Helicobacter pylori bacterium and healing of H. 
      pylori-associated duodenal ulcers. In clinical studies, esomeprazole has shown 
      greater efficacy than omeprazole with a comparable low incidence of adverse 
      events. (c) 2001 Prous Science. All rights reserved.
FAU - Rabasseda, Xavier
AU  - Rabasseda X
AD  - Medical Information Department, Prous Science, Barcelona, Spain. 
      xrabasseda@prous.com
FAU - Cole, Patrick
AU  - Cole P
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
EDAT- 2003/05/10 05:00
MHDA- 2003/05/10 05:01
CRDT- 2003/05/10 05:00
PHST- 2003/05/10 05:00 [pubmed]
PHST- 2003/05/10 05:01 [medline]
PHST- 2003/05/10 05:00 [entrez]
AID - 844210 [pii]
AID - 10.1358/dot.2001.37.11.844210 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2001 Nov;37(11):767-781. doi: 10.1358/dot.2001.37.11.844210.